Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults

Narcisse Patrice Komas¹*, Sumantra Ghosh², Mariama Abdou-Chekaraou³, Pierre Pradat⁴, Nasser Al Hawajri⁵, Alexandre Manirakiza⁶, Gina Laure Laghoë¹, Claudine Bekondi¹, Ségolène Brichier⁷, Jean-Omer Ouavéné⁷, Abdoulaye Sépou³, Brice Martial Yambiyo⁷, Jean Chrysostome Gody⁷, Valentin Fikouma⁶, Athénaïs Gerber⁷, Nataï Abeywickrama Samarakoon², Dulce Alfaiate³, Caroline Scholtès⁴, Nora Martel², Frédéric Le Ga³, Hugo Lo Pinto², Ikram Amrî², Olivier Hantz², David Duranteï², Jean-Louis Lesbordes⁶, Emmanuel Gordien², Philippe Merle², Tudor Drugan¹, Christian Trépo², Fabien Zoulim², Jean-Claude Cortay², Alan Campbell Kay², Paul Dény²,³,⁴

1 Laboratoire des hépatites virales, Institut Pasteur de Bangui, Bangui, Central African Republic, 2 INSERM, U1052, UMR CNRS 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France, 3 Service de Microbiologie Clinique, Hôpital Avicenne, Groupe des Hôpitaux Universitaires Paris Seine Saint-Denis, Assistance Publique–Hôpitaux de Paris, Bobigny, France, Université Paris 13/Sorbonne Paris Cité, UFR Santé Médecine Biologie Humaine, Bobigny, France, 4 Center for Clinical Research, Croix-Rousse Hospital, Lyon, France, 5 Hospices Civils de Lyon, Lyon, France/Université de Lyon I, Lyon, France, 6 Agence de Biomédecine, Saint Denis, France, 7 Service d’Épidémiologie, Institut Pasteur de Bangui, Bangui, Central African Republic, 8 Service de Médecine Interne, Hôpital de l’Amitié, Avenue Indépendance, Bangui, Central African Republic, 9 Service de Gynécologie Obstétrique, Hôpital Communautaire de Bangui, Avenue des Martyrs, Bangui, Central African Republic, 10 Complexe Pédiatric de Bangui, Bangui, Central African Republic, 11 Centre de Traitement Ambulatoire de l’Hôpital Communautaire de Bangui, Bangui, Central African Republic, 12 Laboratoire de Virologie, Croix-Rousse Hospital, Lyon, France, 13 Department of Medical Informatics and Biostatistics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

* These authors contributed equally to this work.
† Deceased.

Citation: Komas NP, Ghosh S, Abdou-Chekaraou M, Pradat P, Al Hawajri N, Manirakiza A, et al. (2018) Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults. PLoS Negl Trop Dis 12(4): e0006377. https://doi.org/10.1371/journal.pntd.0006377

Abstract

Hepatitis delta virus (HDV) increases morbidity in Hepatitis B virus (HBV)-infected patients. In the mid-eighties, an outbreak of HDV fulminant hepatitis (FH) in the Central African Republic (CAR) killed 88% of patients hospitalized in Bangui. We evaluated infections with HBV and HDV among students and pregnant women, 25 years after the fulminant hepatitis (FH) outbreak to determine (i) the prevalence of HBV and HDV infection in this population, (ii) the clinical risk factors for HBV and/or HDV infections, and (iii) to characterize and compare the strains from the FH outbreak in the 1980s to the 2010 HBV–HDV strains. We performed a cross sectional study with historical comparison on FH-stored samples (n = 179) from 159 patients and dried blood-spots from volunteer students and pregnant women groups (n = 2172). We analyzed risk factors potentially associated with HBV and HDV.
Funding: This work was supported by French National Agency for Research on AIDS and Viral Hepatitis (ANRS, contract #12202). PD was supported by an INSERM interface contract from Siemens Diagnostics provide nucleic acids extraction kits and help in the procedure. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: PD and NPK report grants from Agence Nationale de recherche sur le Sida et les Hépatites virales (ANRS #12202) PD reports grants from Institut National de la Santé et la Recherche Médicale, non-financial support from Siemens Diagnostics, during the conduct of the study; personal fees from Gilead, outside the submitted work; In addition, PD has a patent Dény Paul, Radjef Nadja, Huc-Anais Patricia, Molecules d’acides nucléiques d’HDV, leurs fragments et leurs applications, 01 12285 issued to Assistance Publique – Hôpitaux de Paris le 24 septembre 2001; Extension internationale PCT/FR02/03239 au nom de Assistance Publique – Hôpitaux de Paris le 23 septembre 2002, - PD and FLG have a patent Dény Paul, Gault Elyanne, Le Gal Frédéric, « Quantitative detection of HDV » issued to Assistance Publique – Hôpitaux de Paris le 6 aout 2004; Extension internationale PCT/IB2005/002628 au nom de Assistance Publique – Hôpitaux de Paris le 27 juillet 2006. All the other authors have no conflict of interest.

Previous HBV infection (presence of anti-HBc) occurred in 345/1290 students (26.7%) and 186/870 pregnant women (21.4%)(p = 0.005), including 110 students (8.8%) and 71 pregnant women (8.2%), who were also HBsAg-positive (p = 0.824). HDV infection occurred more frequently in pregnant women (n = 13; 18.8%) than students (n = 6; 5.4%) (p = 0.010). Infection in childhood was probably the main HBV risk factor. The risk factors for HDV infection were age (p = 0.040), transfusion (p = 0.039), and a tendency for tattooing (p = 0.055) and absence of condom use (p = 0.049). HBV-E and HDV-1 were highly prevalent during both the FH outbreak and the 2010 screening project. For historical samples, due to storage conditions and despite several attempts, we could only obtain partial HDV amplification representing 25% of the full-length genome. The HDV-1 mid-eighties FH-strains did not form a specific clade and were affiliated to two different HDV-1 African subgenotypes, one of which also includes the 2010 HDV-1 strains. In the Central African Republic, these findings indicate a high prevalence of previous and current HBV-E and HDV-1 infections both in the mid-eighties fulminant hepatitis outbreak and among asymptomatic young adults in 2010, and reinforce the need for universal HBV vaccination and the prevention of HDV transmission among HBsAg-positive patients through blood or sexual routes.

Author summary

In the Central African Republic (CAR), due to 20 years of conflict, the health system has been disorganized. This could contribute to maintenance of high transmission levels of Hepatitis B Virus (HBV) and its satellite Hepatitis Delta Virus (HDV). This work studies the evolution of both infections 25 years after a fulminant hepatitis (FH) outbreak occurring in the mid-1980s associated with HDV superinfection. In young asymptomatic adults, the results show that both HBV and HDV were still actively circulating in CAR in 2010. Indeed, more than one third of HBV-infected individuals were chronic HBV carriers. Furthermore, HDV infection could be spreading among 10% of them through blood and sexual transmission. The past FH outbreak and contemporary infections were both associated with heterogeneous HDV-1 strains, combined with HBV-E. Vaccination against HBV was uncommon among pregnant women and students, even among medical students. The study constitutes warning signals to help CAR health-care reconstruction and underlines the importance of HBV vaccination. The high level of HBV infection creates a background for HDV superinfection. Neonatal HBV vaccination is needed, together with vaccination of unprotected populations. Awareness of health authorities as well as the general public would help reduce HBV and HDV infections.

Introduction

Hepatitis B virus (HBV) infection can be prevented by vaccination, which can obviate progression of chronic liver disease to cirrhosis, liver failure and hepatocellular carcinoma. However, owing to limited access to vaccination during the past 30 years in resource-poor countries, more than 2 billion people have been infected with HBV and approximately 257 million remain chronic carriers, especially those infected at birth or in early childhood [1].

Viral hepatitis can be associated with acute severe illness, sometimes leading to fulminant destruction of the liver parenchyma or to chronic inflammatory-based injury, resulting in liver
remodeling and regeneration that contributes to fibrosis and early carcinogenic events. Both acute co-infection with HBV and hepatitis D virus (HDV) and superinfection of chronic HBV carriers by HDV can aggravate these clinical spectra [2,3], sometimes leading to fulminant hepatitis (FH) at higher rates than in HBV monoinfection. In the early years after HDV discovery, HDV co- and super-infection profiles accounted respectively for 58% and 42% of delta-associated FH in Western Europe [4]. Furthermore, liver fibrosis accelerates in chronic HBV and HDV infections and HDV may have a role in carcinogenesis [5, 6]. A recent meta-analysis studying the prevalence of HDV infection in Sub-Saharan countries indicated that in countries surrounding CAR, such as Cameroon, anti-HD Ab prevalence was up to 14% of HBsAg-positive individuals from a national survey [7]. Furthermore, in the Central African Republic (CAR) among patients followed up in hepatology clinics, the anti-HD prevalence reached 50% and this prevalence was 18% in patients with HCC [7].

Although HDV was identified only 40 years ago [3], it has probably been present in humans for a long time. The virus is ubiquitous, and the prevalence of HDV infection among HBsAg-carriers may vary from 0.5% to 40%, depending of the geographical area studied [2]. A global estimation of HDV-infected population suggests that 10–20 million HBV-infected people have encountered HDV. The virus has high genetic variability, especially in Africa, Amazonia and Asia [8,9]. Currently, the Deltavirus genus comprises eight major clades, or genotypes, labelled HDV-1 to HDV-8 [9,10]. HDV-1 is ubiquitous while HDV-2 and HDV-4 in Asia and HDV3 in Amazonia are geographically restricted. HDV-5–HDV-8 have a clear African origin but may be found elsewhere, due to slave trading and human migration [9,11]. While HBV is a DNA virus with a reverse transcriptase targeted by antiviral drugs, HDV RNA replicates by hijacking the cellular RNA polymerase II. Therefore, chronic hepatitis due to HBV–HDV is the most difficult-to-treat of all severe virally-induced liver diseases [12–14]. Even though therapeutics are available for chronic HBV or HCV infections, about 15 million HBV–HDV-infected patients worldwide await efficient therapy. Alpha-Interferon or Pegylated-IFN that are currently the sole anti-HDV authorized drugs, may be of limited efficacy in less than one third of infected patients. Furthermore, addition of Adefovir or Tenofovir or Entecavir to Pegylated-IFN does not improve the sustained response rate among HDV-1-infected patients, underlining the importance for developing new approaches [12,14]. Indeed, new strategies, such as viral entry competitors, farnesyl transferase inhibitors and nucleic acid polymers are nowadays promising, even if they are still upstream from a wide clinical use [14].

The severity of HBV–HDV infections could be due to particular evolutionary and/or geographical combinations of HBV–HDV genotypes, and some HBV–HDV pairs may be more pathogenic than others [15,16]. In the mid-1980s, cases of severe acute liver failure in Bangui, Central African Republic (CAR), were associated with an HDV outbreak. At least 124 cases of FH occurred among 154 cases of jaundice at Bangui University Hospital, and 88% of the patients died [17]. The evolution of HDV has not been studied since the outbreak, although the high prevalence of HBV infection [18] and the global instability in CAR constitute a potential background for the spread of HDV that may lead to severe chronic liver disease and increased risk of dying from liver failure. Furthermore, although a national HBV preventive program is still conducted, the civil war in the country might have maintained high levels of HBV and HDV transmission through injuries, blood and sexual contacts, mother-to-child transmission and even unsafe blood transfusion. Indeed, viral hepatitis infections, especially hepatitis B, are likely to continue to be a major problem in the near future in CAR. Therefore, it seems crucial to reappraise the level of HBV and HDV infection in young CAR patients to specify the level of unprotected persons that may benefit from catch-up vaccination, if they are free of infection, and those that might be included in future therapy protocols at a time where
the World Health Organisation reflexion encourages specific hepatitis funding among infectious diseases global health strategies.

The aims of our study were (i) to determine the prevalence of HBV and HDV infection in young asymptomatic students and pregnant women born at the end or after the end of the FH outbreak, (ii) to determine possible clinical risk factors for HBV and/or HDV infections in this population and (iii) to characterize and compare the strains from the FH outbreak in the 1980s to 2010 HBV–HDV strains.

**Methods**

We performed a cross sectional study with historical comparison.

**Prospective study population**

Two cohorts, volunteer students (n = 1298) and pregnant women (n = 874), were prospectively sampled between January and December 2010 (S1 Method and S1 Table). Based on volunteering, students came from almost all public and private high schools in Bangui, the capital of CAR, and all different departments of the University of Bangui (S2 Table). Objectives of the study were carefully explained to high-school directors and to the university general secretary in order to obtain authorisation. The investigators then organized information meetings in each secondary school and faculty before distributing the information notice. Written consent forms were obtained from those who freely accepted to participate to the study. Therefore, this recruitment should be considered as passive. Interested students filled the questionnaire anonymously. Recruitment of pregnant women (PW) was performed in all public health structures (n = 6) with maternity wards in Bangui. In these places, medical staffs, including qualified midwives involved in the Mother-to-Child HIV transmission prevention (MCTP), were responsible for sampling. PW coming for prenatal consultation were sampled (dried blood spot) after an initial pre-test counselling. All consecutive pregnant women that accepted to participate to the study signed the consent form and answered the epidemiological questionnaire. Those who had an HBsAg positive result were then followed at the 2 reference public hospitals: “Communautaire” and “l’Amitié”, under the supervision of one of us (AS). No recruitment occurred in private clinics. In all, 874 consecutive pregnant women agreeing to participate were included. The information asked for all participants included gender, age, place of living in Bangui, occupation, marital status, personal viral hepatitis history and previous HBV vaccination. Risk factors investigated were surgery, dental extraction, blood transfusion, IVDU, tattooing, use of sharp tool, alcohol intake and sexual risk factors including ancient and actual sexual partners and use of condom (S1 Method: French-to-English translated questionnaire).

**Ethical approval**

The study protocol was approved by the Scientific Committee of the Faculty of Medicine (CSVPRS, 12/2009; University of Bangui, CAR) and by a French ethical committee (CCPBRB, CPP 09024/2009; Saint-Germain-en-Laye, France) under ANRS guidelines. Written informed consent was obtained from all participants. For subjects under 18, parental consent was obtained. Each participant or parent was individually informed of the results of the serological tests.

**Samples**

1984–1987 outbreak: Archived samples had been conserved in a cold room (−20°C) in Lyon, France, since the FH outbreak [17]. For HBsAg serological studies, we used 179 serum samples
from 159 individuals, including patients and close relatives or health-care workers (HCWs), sampled at the same time. Because of insufficient volumes, we conducted molecular analyses for only 133 samples from FH patients and close relatives or HCWs. However, we could not distinguish between these categories because the identifiers were no longer available.

Specimen collection in 2010: Dried blood spots (n = 6/individual) were prepared as described previously [18]. Filter papers were sealed and stored at the Institut Pasteur de Bangui at –20˚C with desiccant until serological assay. To ensure enough sample for molecular analyses of HBV and HDV, 10 mL of total blood were taken from the HBsAg-positive volunteer students (see below) and conserved at –80˚C.

Serological assays
Dried blood spots were examined as described previously [18]. All three markers HBsAg, anti-HBc and anti-HBs tests (Abbott-Murex, United Kingdom) were performed according to the manufacturers’ instructions in 2160 individuals’ samples. HBsAg-positive results were confirmed in the Murex HBsAg Confirmatory test, Version 3. HBsAg-positive samples from the 1985 (n = 84) and 2010 (n = 181) serum collections were screened for HDV with the anti-HDV total antibody test and HDAg detection tests (diaSorin, Italy).

HBV and HDV viral loads and sequence analysis
From the 114 HBsAg-positive students contacted, 82 individuals agreed to give serum samples for molecular analyses, including all HDV-infected students. Studies were performed at the University Paris 13, Bobigny, France, as previously described [19,20].

Archived sample extraction and amplification
To avoid contamination with recent samples, archived samples were extracted and amplified in a separate laboratory in Lyon, France. Initially, Macherey-Nagel extraction procedures were used for 40 samples using RNA and DNA extraction kits to explore both HBV and HDV genotypes, respectively. For subsequent samples, due to the conservation conditions, all efforts were focused on HDV RNA detection and characterization. Total nucleic acids were extracted by an automated procedure (VERSANT® kPCR, Siemens Healthcare). Control water extraction was included for every 10 samples. A 400 base pair HDV fragment was amplified according to reference [9]. (dx.doi.org/10.17504/protocols.io.mtdc6i6) with HiFi Kapa polymerase (KapaBiosystems). This RT-PCR procedure has been shown to be of higher sensitivity than the RT-qPCR approach [21] and was chosen to minimize the risk of underestimation of the results because of the sub-optimal conservation conditions of the historic samples (-20˚C during 25 years). To amplify the full-length L-HD gene, we designed a 5’ primer corresponding to the seven first codons of HDV-1 sequences. For HBV genotyping, PreS1 and PreC-C genes were amplified according to [19] (dx.doi.org/10.17504/protocols.io.m8jc9un and dx.doi.org/10.17504/protocols.io.mixc4fn, respectively). Unfortunately, despite many attempts, full-length sequence analysis of mid-eighties FH-associated strains was unsuccessful. Sequence analysis and phylogenetic studies were conducted with different models and Bayesian reconstruction, as described previously [9,10,20].

Statistical analysis
Sample size was calculated with the following formula taking into account potential cluster effects:
\[ N_0 = D \sigma^2 p q / i^2 \] where \( N_0 \) is the sample size, \( p \) the expected HBV prevalence, \( q = 1 - p \), \( D \) the cluster effect (set at 1), and \( i \) the acceptable precision (set at 2%). Considering a theoretical HBsAg prevalence among students of 15% [18], the calculated sample size is 1257 \((z = 1.96)\). For pregnant women, the required sample size based on a theoretical prevalence of 13% is 1087. Results are presented as numbers and percentages for qualitative variables, and as means +/- standard deviations (SD) for quantitative variables.

Pearson Chi-squared or, when necessary, Fisher exact tests were used to compare categorical data between the different groups. For continuous data, Student’s t test was used. Multivariate analysis using logistic regression was performed to identify factors potentially associated with HDV. A p value <0.05 was considered statistically significant. Statistical analyses were performed using SPSS for Windows Version 19.0 (IBM Corp., Armonk, NY, USA).

Results

**HDV serological assay results in the historical cohort**

Among the 159 individuals, identifiers of their status such as health care worker were no longer available, although four family clusters (n = 6, 6, 2, 2 members, respectively) could be distinguished. Therefore, to study hepatitis delta markers, we retrospectively focused on samples having an HBsAg positive result (n = 94 patients). For 84 of them (89.4%), both HDAg and total anti-HD Ab were tested using commercial ELISA tests. Results are described in Table 1. HDAg and anti-HD total Ab tests were both positive in 4/84 samples, HDAg was the only positive delta marker in 24/84 samples and anti-HD total Ab was the only marker in 23/84 samples, making 51/84 (60.7%) samples that had at least one positive HDV serological marker. These results are to be regarded in the context of the fulminant acute HDV/HBV outbreak, at a time when anti-HD Abs could not be detectable in a large number of samples corresponding to Day1, Day2 or Day3 of the severe acute liver disease.

| Prospective cohort (n = 2172) | Students (n = 1298) | Pregnant women (n = 874) | Total (n = 2172) | \( P^1 \) | Historical cohort (n = 159) |
|-----------------------------|---------------------|--------------------------|-----------------|----------|-----------------------------|
| Age (mean ± SD) (n = 2170)  | 21.9 ± 4.0          | 25.0 ± 5.7               | 23.1 ± 5.0      | <0.001   | ND                          |
| Sex (F/M) (n = 2170)        | 448/848             | 874/0                    | 1322/848        | <0.001   | ND                          |
| Previous vaccination (n = 2165) | 20 (1.5%)         | 23 (2.6%)                | 43 (2.0%)       | 0.074    | ND                          |
| HBsAg positive\(^2\) (n = 2160) | 110 (8.5%)        | 71 (8.2%)                | 181 (8.4%)      | 0.824    | 94/154 (61.3%)              |
| Anti-HBc IgG positive (n = 2160) | 345 (26.7%)       | 186 (21.4%)              | 531 (24.6%)     | 0.005    | ND                          |
| Anti-HBc IgG positive among HBsAg negative (n = 1979) | 235 (19.9%) | 115 (14.4%) | 350 (17.7%) | 0.002 | ND |
| HBsAg and/or anti-HBc IgG positive (n = 2160) | 345 (26.7%) | 186 (21.4%) | 531 (24.6%) | 0.005 | ND |
| Anti-HDV Ab positive\(^3\) | 5/110 (4.5%) | 13/69 (18.8%) | 18/179 (10.0%) | 0.004 | 27/84\(^4\) (32.1%) |
| HDAg positive\(^4\) | 1/110 (0.9%) | 0/69 (0.0%) | 1/179 (0.5%) | 1.000 | 28/84\(^4\) (33.3%) |
| HDV infection\(^5\) | 6/110 (5.4%) | 13/69 (18.8%) | 19/179 (10.6%) | 0.010 | 51/84\(^4\) (60.7%) |

\(^1\)Comparison Students versus Pregnant Women
\(^2\)Five patients among 2165 having HBsAg positive results did not have anti-HBc testing and were discarded from this analysis
\(^3\)Among 179 recent HBsAg-confirmed positive results
\(^4\)Due to insufficient serum volumes HDV serological tests were performed on 84/94 HBsAg-positive historical samples. Four patients had both HDAg and anti-HD Ab positive results
\(^5\)Considering positive Anti-HDV Ab and/or positive HDAG results

https://doi.org/10.1371/journal.pntd.0006377.t001
Prospective 2010 survey

HBV infection was highly prevalent in this highly-educated young asymptomatic population. When anti-HBc was used as a marker of previous HBV infection among 2160 individuals, 345 students (26.7%) and 186 pregnant women (21.4%) had encountered HBV at some time (Table 1). HBsAg was present in samples from 110 students (8.5%) and 71 pregnant women (8.2%) \( (p = 0.824) \) (Table 1). Of the 531 subjects positive for anti-HBc, 181 (110 + 71) had HBsAg detectable in their serum, indicating a high chronicity rate of 34.1%. As the risk of becoming a chronic carrier is higher in young children than in adolescents or adults and because no significant known adult risk factors of transmission emerged when comparing HBV-positive versus HBV-negative individuals (Table 2 and S3 Table and S4 Table), this result may indicate that possible major routes for HBV infection were (i) being born from an HBsAg-positive mother or (ii) being infected in the very first years of life. To avoid confounding factors, each cohort was also studied specifically comparing the HBV-non infected versus the HBV-infected individuals (S5 Table and S6 Table). Age was slightly significantly associated to HBV previous or current infection in students, whereas previous hepatitis and alcohol intake were identified as risk factors in the pregnant women group.

HDAg and total anti-HD (IgM/IgG) were studied in sera from 110/110 (100%) HBsAg-positive students and 69/71 (97.2%) HBsAg-positive pregnant women. Five students and 13 pregnant women had anti-HD antibodies in their serum, and one student, without detectable anti-HD, had a positive HDAg result thus considered to have acute hepatitis D. Therefore, the prevalence of HDV infection was 6/113 students (5.4%) and 13/69 pregnant women (18.8%). Indeed, whereas HBsAg prevalence was similar between the two groups, HDV prevalence was significantly higher among pregnant women than students (Table 1, \( p = 0.010 \)). The possible contributing factors for HDV acquisition were a higher mean age \( (p<0.001) \), higher rates of previous blood transfusion \( (p<0.039) \) and tattooing \( (p<0.055) \) and a lower rate of condom use \( (p = 0.049) \) (Table 3). Concerning this last point, we could not rule out a confounding factor as pregnant women obviously did not always have condom-protected sex and were significantly more frequently infected with HDV than students. On the other hand, we cannot exclude age as an HDV increased risk factor, as this was found, although non significantly, in each cohort considered independently (S7 Table and S8 Table). Because the end of the fulminant hepatitis outbreak occurred late 1987, older students and pregnant women would have been born when HDV transmission risk was still present.

HBV DNA amplification and sequencing

Nucleic acid testing for HBV sequences was achievable for 40 historical samples with sufficient residual volume, and the Pre-C/C region of HBV could be amplified and sequenced from eight samples. Seven sequences were of HBV genotype E and one of genotype A2 (S1A Fig). For the contemporary survey, of the 110 HBs-Ag positive students, 82 (71.9%) agreed to return for medical examination and virus analyses. The HBV DNA viral loads were quantified, except for two samples, in which amplification failed. In the 80 remaining samples, HBV-DNA was undetectable in seven (8.75%), at a low level \( (< 3.3 \log_{10} \text{IU/mL}) \) in 33 (41.25%) at a medium level \( (> 3.3 < 8.3 \log_{10} \text{IU/mL}) \) in 18 (22.5%) and at a high level \( (> 8.23 \log_{10} \text{IU/mL}) \) in 22 (27.5%), indicating that half of the asymptomatic students had moderate-to-high viral replication. Amplification of the Pre-S1 coding region of the HBV genome resulted in 50 interpretable HBV sequences that were submitted to Bayesian analyses with reference sequences (S2A Fig). Tree reconstruction indicated that most of CAR2010 were of HBV genotype E \( (n = 48) \) whereas 2 CAR2010 strains corresponded to HBV_DE recombinants (S2A Fig and S1B Fig).
and S2B Fig). In addition, we then aimed to amplify the PreC/C from 2010 CAR HBV strains and obtained 35 sequences all affiliated to HBV genotype E (S1B Fig). We also tried to amplify the Pre-S1 coding region from the 40 HBsAg positive historical samples for which DNA had been extracted, focusing on HBsAg-positive ones. We could obtain 5 Pre-S1 sequences corresponding to 3 patients with fulminant hepatitis (HF2, HF19 and HF27). Tree reconstruction, focused on HBV D and E genotypes, indicates that all three FH-associated HBV strains corresponded to HBV_E genotype and one of them could cluster with one CAR2010 HBV strain (S2B Fig).

Table 2. Comparison of HBV status among young asymptomatic adults (students and pregnant women) in Bangui, Central Africa Republic (CAR) in 2010.

| Anti-HBc antibodies AND/OR HBsAg | Negative (n = 1631) | Positive (n = 531) | p |
|----------------------------------|---------------------|---------------------|---|
| Group                            | Students (n = 1296) | 947 (73.1%)         | 349 (26.9%) | 0.002 |
|                                  | Pregnant Women (n = 866) | 684 (79.0%)         | 182 (21.0%) | |
| Age (years; mean ± SD)           | 23.1 ± 5.0          | 23.3 ± 5.0          | 0.456 |
| Female:Male                      | 997:634             | 317:214             | 0.558 |
| Marital status (n/%)             |                     |                     | 0.156 |
| Single                           | 1378 (84.5%)        | 454 (85.5%)         | |
| Live-in partnership              | 133 (8.2%)          | 50 (9.4%)           | |
| Married (monogamous)             | 89 (5.5%)           | 18 (3.4%)           | |
| Married (polygamous)             | 29 (1.2%)           | 7 (1.3%)            | |
| Widowed                          | 2 (0.1%)            | 2 (0.4%)            | |
| District Address in Bangui       |                     | See details in S3 Table | 0.769 |
| Occupation                       |                     | See details in S4 Table | 0.600 |
| CAR nationality                  | 1620 (99.3%)        | 526 (99.1%)         | 0.561 |
| Risk factors                     |                     |                     | |
| Previous viral hepatitis (n = 2045) | 27 (1.8%)          | 15 (3.0%)           | 0.094 |
| Previous icterus (n = 2148)     | 132 (8.2%)          | 55 (10.4%)          | 0.112 |
| Surgery (n = 2162)               | 126 (7.7%)          | 44 (8.3%)           | 0.677 |
| Dental extraction (n = 2155)     | 491 (30.2%)         | 138 (26.1%)         | 0.080 |
| Blood transfusion (n = 2152)     | 75 (4.6%)           | 26 (4.9%)           | 0.874 |
| Tatoo (n = 2162)                 | 102 (6.3%)          | 35 (6.6%)           | 0.782 |
| Intravenous drug use (n = 2162)  | 8 (0.5%)            | 3 (0.6%)            | 0.531 |
| Sharp-edged tool use (n = 2162)  | 851 (52.2%)         | 270 (50.8%)         | 0.594 |
| Alcohol (n = 2162)               | 784 (48.1%)         | 264 (49.7%)         | 0.509 |
| Multiple partners before (n = 2162) | 579 (35.5%)        | 201 (37.9%)         | 0.327 |
| Multiple partners in 2010 (n = 2162) | 98 (6.0%)         | 35 (6.6%)           | 0.627 |
| Use of condom-(n = 2075)         |                     |                     | |
| Always                           | 414 (26.4%)         | 147 (29.0%)         | 0.045 |
| sometimes                        | 375 (23.9%)         | 140 (27.6%)         | |
| never                            | 779 (49.7%)         | 220 (43.4%)         | |
| Previous HBV vaccination (n = 2156) | 31 (1.9%)          | 11 (2.1%)           | 0.801 |

https://doi.org/10.1371/journal.pntd.0006377.t002
HDV RNA amplification and sequencing

Among 88 of the 94 HBsAg-positive historical samples (Table 1) that were available for HDV molecular studies, a 400-bp target encompassing the 3' coding region of the LHD gene was successfully amplified, cloned and sequenced from 12 HDV-infected patients. Full-length LHD gene amplification from historical samples was successful in only three cases, although several clones were sequenced from each. For the 2010 samples from the 6 HDV-positive students, the 400-bp target could be amplified in five cases from both serum and dried blood spot and from serum only in one case. All sequences from historical and contemporary samples were unambiguously belonging to the HDV-1 genotype (Fig 1). A Bayesian reconstruction consensus tree, obtained using CAR historical and contemporary sample sequences from this study, African (Cameroon, CAR, Chad, Côte d’Ivoire) sequences (S9 Table), and sequences retrieved from databases, is displayed in Fig 1. The database sequences included the eight HDV genotype-prototype sequences (shown in red in Fig 1) and other HDV-1 CAR sequences characterized in 2009 [22].

The topology of the tree clearly indicates that the FH viral sequences do not form a specific historical clade. Thus, all HDV sequences from the HF-mid-eighties strains did not derive
Fig 1. Phylogenetic analysis of HDV partial genome (400 bp) comparing mid-eighties delta fulminant hepatitis clones (FH1985) to HDV direct sequences (CAR2010) sampled in 2010 from serum (s) and dry blood spot (d) among HBV and HDV in CAR.
We aligned 45 cloned sequences from the 12 FH strains obtained from the historical cohort (labelled ‘1985’ in green) and the 6 strains obtained from asymptomatic students in 2010 represented in duplicate from serum (s) and dried blood (d) (labelled ‘2010’ in blue). We also included 1 strain from a hospitalized case of acute HDV hepatitis in Bangui in 2010 (sd525-CAR2010) and HDV-1 sequences from 9 African samples characterized in Bobigny (dFr) or Lyon (dLy), France, in addition to CAR HDV sequences published by Andernach and coworkers [22], sampled in 2009. Further comparison included HDV strains from various parts of the world and genotype-reference prototypes (labelled in red). Bayesian analyses (10M generations) gave the consensus tree represented in Fig 1, after discarding 25% of trees from early topology exploration. Branch values indicate posterior probabilities >0.9. Interestingly, the fulminant 1985 and asymptomatic student 2010 strains are all affiliated to HDV-1 with a 100% posterior probability value (thick branch) and the clade topology do not distinguish the mid-eighties strains from the 2010 strains.

https://doi.org/10.1371/journal.pntd.0006377.g001

Discussion

To study the persistence of hepatitis B and hepatitis Delta viruses twenty-five years after a major HDV and HBV FH outbreak in an equatorial city in Africa, we conducted a prospective search among young healthy adults in 2010. The study was not designed to specify HBV and HDV prevalence in extensive Bangui populations, but was focused on individuals born at or after the end of the epidemic outbreak, to assess viral long-term continuance. After patient inclusion, questionnaire filling and screening, further actions included volunteer-based HBV vaccination and medical examination, for seronegative individuals and HBsAg-positive carriers, respectively.

An important observation is that both HBV and HDV are still actively circulating in CAR. Indeed, both students and pregnant women had a high prevalence of previous HBV infection and HBsAg-chronic carriage. In this survey, including a highly educated population, more than one third of HBV-infected individuals were chronic carriers. It has been estimated that 90% of newborns infected at or shortly after birth will become HBV carriers, although this rate decreases with age, until less than 5–10% for adolescent or adult HBV-infections [24]. In this study, most of the students and pregnant women who were anti-HBc-positive had probably been infected at an early age, indicating the importance of sustaining an anti-HBV vaccine
strategy for newborns in CAR. Furthermore, HDV could be amplified from all six students with anti-HD or HDAg, indicating continuing HDV replication and an active reservoir that also could have been prevented by early anti-HBV vaccination. Indeed, an important issue corresponds to the fact that a very low prevalence of earlier anti-HBV vaccination (<2%) was observed and that a failure for students to participate for a de novo free anti-HBV vaccination was evidenced, both indicative of HBV (and HDV) potential acquisition in adulthood. HDV infection was still active in 2010 cohorts, however, due to our study design focused on asymptomatic young adults, no fulminant hepatitis was observed in 2010 infections. By comparison, a study conducted in the Democratic Republic of Congo revealed than HBV-HDV could be found in 26.1% of acute febrile jaundice samples from a national yellow fever survey from 2003 to 2011 [25].

In CAR, HBV-E and HDV-1 were present in the 1980s and 2010 and no specific fulminant hepatitis-associated HDV strain pattern was clearly evidenced comparing 1980s to 2010

| A)                      | CRB          | LZL          | NLS          | NLS          | ARM1         | HMG         |
|-------------------------|--------------|--------------|--------------|--------------|--------------|-------------|
| strategy for newborns   |              |              |              |              |              |             |
| strategy for newborns   |              |              |              |              |              |             |
| strategy for newborns   |              |              |              |              |              |             |

**Fig 2. Alignment of the L-HDAg amino acid deduced sequences from fulminant-associated isolates from the historical cohort (1985) and from young asymptomatic HDV-infected students (2010).** The alignment is compared together with L-HDAg sequences from HDV-1 prototype (Italy, Accession Number: X04451) and HDV-3 prototype (Peru-1, Accession Number: L22063), representing the prototypes of two HDV genotypes associated with fulminant hepatitis outbreaks. Dots represent the same amino acid as in the Italy prototype and question mark ambiguities. A: Full-length coding sequences (214 codons) were obtained for 3 FH isolates (FH27, FH88, FH123). B: COOH terminal part of L-HDAg of the corresponding HDV 1985 (45 FH clones) and 2010 (seven) sequences associated to asymptomatic infections. Note that all the African sequences have the A202S mutation and that FH27 clone 4 has a frameshift mutation of the carboxy-terminal end of L-HDAg (ORF-K), leading to the disappearance of the farnesylation CXXX box.

https://doi.org/10.1371/journal.pntd.0006377.g002

strategy for newborns in CAR. Furthermore, HDV could be amplified from all six students with anti-HD or HDAg, indicating continuing HDV replication and an active reservoir that also could have been prevented by early anti-HBV vaccination. Indeed, an important issue corresponds to the fact that a very low prevalence of earlier anti-HBV vaccination (<2%) was observed and that a failure for students to participate for a de novo free anti-HBV vaccination was evidenced, both indicative of HBV (and HDV) potential acquisition in adulthood. HDV infection was still active in 2010 cohorts, however, due to our study design focused on asymptomatic young adults, no fulminant hepatitis was observed in 2010 infections. By comparison, a study conducted in the Democratic Republic of Congo revealed than HBV-HDV could be found in 26.1% of acute febrile jaundice samples from a national yellow fever survey from 2003 to 2011 [25].

In CAR, HBV-E and HDV-1 were present in the 1980s and 2010 and no specific fulminant hepatitis-associated HDV strain pattern was clearly evidenced comparing 1980s to 2010

| B)                      | CRB          | LZL          | NLS          | NLS          | ARM1         | HMG         |
|-------------------------|--------------|--------------|--------------|--------------|--------------|-------------|
| strategy for newborns   |              |              |              |              |              |             |
| strategy for newborns   |              |              |              |              |              |             |
| strategy for newborns   |              |              |              |              |              |             |
strains. During the FH outbreak in Bangui in the mid-1980s, the disease was associated with specific pathological lesions (spongiocyte-associated hepatitis) involving lympho-plasmocytoid infiltrates, lesions of eosinophilic necrosis and massive macro- or micro-vacuolar steatosis, giving cells a particular “morula-like” type and resulting in a high mortality rate [17,26]. Such strain-associated lesions could be propagated in the woodchuck model [26]. Similar lesions have been described in South American FH outbreaks [27,28] that were linked to HDV-3, usually associated with HBV-F, although HBV-A and HBV-D have also been implicated in Amazonia [29,30]. In Bangui, the outbreak involved HDV-1, here associated with HBV-E. This particular histopathological type of FH, associated with high mortality, was therefore not due to a single HBV–HDV genotypic association. During the outbreak, it may be hypothesised that a recent combination of different HDV-1 subgenotypes with the Twentieth Century-introduced African HBV-E helper, rather than HBV-A or HBV-D, could have resulted in a severe disease. Such an explanation was suggested in a study in Taiwan, where the spread of HDV-1 to the Asian HBV-B and HBV-C genotypes resulted in more FH than the indigenous HDV-2 [31]. Alternatively, there may be in equatorial rainforests some as yet unrecognised cofactor that might increase the number of cases of fatal acute liver failure observed in both CAR and Amazonia [25,32].

In this study, the potential role of specific HDV-1 strains or its HDAg protein in the pathological lesions was looked for. We found no evidence of a specific HDV-1 fulminant associated clade. Indeed, within the limits of the sequences obtained, the 1985 HDV-1 FH strains were indistinguishable from asymptomatic-associated 2010 HDV-1 strains. Due to conservation conditions since the outbreak, we were unfortunately unable to amplify full-length FH-associated HDV genomes, even using many different approaches. This obviously cannot rule out some specific virulence factors that could have been deduced from comparison of full-length genomes between historical fulminant strains and recent asymptomatic-associated strains. The FH strains and their HDAg sequences intermingle with strains isolated from 2010 asymptomatic patients in CAR and with strains isolated elsewhere in Africa. The only exception corresponded to one HDV clone that displayed a frameshift mutation at the 3’ terminus of the \( L-HDAg \) gene that would eliminate the farnesylation signal of \( L-HDAg \) (Fig 2, FH27 clone 4). This may affect virion assembly and perhaps induces intracellular retention of viral component that may accumulate in infected cells. This variant was observed only once among 45 clones analysed from 12 FH-HDV strains. However, it can be hypothesised that mutants leading to intracellular retention may not easily egress from the infected-cell and might therefore be under-represented in the serum. In addition, they may be potentially cytopathic for the infected hepatocytes. For example, in HBV monoinfection of the human hepatocyte, retention of HBV-PreS1 mutants results in specific pathological lesions known as “ground-glass” hepatocytes [33].

It is disappointing that vaccination against HBV is so uncommon among pregnant women and students with a high education level, even among medical students. Neonatal vaccination (DTP-HepB-Hib) has been practised in CAR since 2008, but coverage is still not universal (http://www.gavi.org), in part due to civil unrest. At present, there is also no HBV immunotherapy nor immediate vaccination of neonates born outside hospitals, in the absence of qualified midwives [1]. Indeed, modelisation has suggested that the proportion of new chronic cases arising from mother-to-child transmission may increase by up to 50% in 2030 [34]. Neonatal anti-HBV vaccination is urgently needed, preferably including a dose as near as possible after birth. Ideally, vaccination of as yet unprotected young populations should also be sustained [1,34]. Meanwhile, at least 8% of the young population of Bangui is at risk for further HDV superinfection and related liver damage. The situation outside of the nation’s capital is probably worse as a recent evaluation has estimated an HBsAg rural prevalence of 11.65% in CAR [35]. The results of this study should clearly contribute to sensitise the health authorities to
consider HBV and HDV infections as a major health challenge in the Central African Republic, and could lead to specific surveys, screening and medial actions among populations at risk of HBV acquisition and/or transmission.

Supporting information

S1 Checklist. STROBE statement.

S1 Table. Age, marital status, district address in Bangui, and blood borne and sexual risk factors in students and pregnant women in Central Africa Republic (CAR) in year 2010.

S2 Table. Students repartition among high schools and University departments. This list corresponds to almost all different high educational entities in Bangui, Central African Republic.

S3 Table. Place of living of the studied cohort in the different districts (1–8) of Bangui capital and Bimbo suburbs district in function of HBV and HDV status. The gray scale indicates the economical status of the district.

S4 Table. Occupation of subjects from the 2 cohorts (student and pregnant women) in function of HBV and HDV status.

S5 Table. Comparison of age, marital status, and blood borne and sexual risk factors in students infected or non-infected by HBV (HBV positive versus negative) in CAR in year 2010.

S6 Table. Comparison of age, marital status, and blood borne and sexual risk factors in pregnant women infected or non-infected by HBV (HBV positive versus negative) in CAR in year 2010.

S7 Table. Comparison of age, marital status, and blood borne and sexual risk factors in students infected or non-infected by HDV (HDAg ± anti-HD Abs positive versus negative) in CAR in year 2010.

S8 Table. Comparison of age, marital status, and blood borne and sexual risk factors in pregnant women infected or non-infected by HDV (HDAg ± anti-HD Abs positive versus negative) in CAR in year 2010.

S9 Table. HDV sequences from this study

| Type         | Accession |
|--------------|-----------|
| Unique Name Study | PRJEB24597 |
| ena-STUDY-Research Cancer Center of Lyon | 24-01-2018-10:05:53:847–48 |
| European Nucleotide Archive (ENA) |          |
S1 Fig. A: Consensus tree obtained from the PreC-C region of the HBV genome (nt1814–nt2495) of reference sequence from Galibert et al. (Nature. 1979). HBV DNA was amplified from DNA extracted from the 40 initial ancestral samples with Macherey Nagel extraction procedures. Amplification yielded positive results in 8 samples, and DNA was directly sequenced from both strands. Corresponding sequences were submitted to alignment by Clustal Omega (http/EBI), with 57 references sequences corresponding to pure HBV genotypes and subgenotypes enriched with HBV-E and DE recombinants [19] and submitted to Bayesian analyses. B: Consensus tree obtained from the PreC-C region of the HBV genome (nt1821-nt2066), focused on HBV A, D and E genotypes. HBV DNA was amplified and sequenced from 2010 samples (35 HBV PreC-C sequences). Alignment was manually corrected and submitted to distance models and Bayesian inference. Note that phylogenetic information of the PreC-C region could not well differentiate HBV_D and HBV_E genotypes.

(SPS)

S2 Fig. A: Consensus tree obtained from PreS1 region analysis of the HBV genome (nt 2817–nt81) of reference sequence from Galibert et al. (Nature. 1979) obtained from 49 isolates from asymptomatic HBV-infected students sampled in Bangui in 2010. PreS1 sequences were obtained by hemi-nested PCR as previously described [20]. Bayesian analyses were conducted on 3.10E6 generation; 25% of initial searches was discarded. Note that 48 isolates belong to the E clade and that using the PreS1 region genotypes D, E and G were affiliated together with a 100% posterior probability value at the original common branch, whereas each of the 2 clades E and D had a pp of only 50%. This may be related to the sequences located in between, including FN594771, known to be D/E recombinant strains. B: Consensus tree obtained from PreS1 region analysis of the HBV genome (nt2838-nt58), focused on HBV_D and HBV_E genotypes. Note that historic sequences FH2, FH19 and FH27 were affiliated to HBV_E genotype strains, one of them clustering with a 2010 CAR HBV sequences s506preS1.

(SPS)

S1 Method. French to English translated questionnaire.

(DOCX)

Acknowledgments

We thank ANRS staff for helpful discussion and Siemens Diagnostics for providing nucleic acids extraction kits and help in the procedure.

Author Contributions

Conceptualization: Narcisse Patrice Komas, Jean-Omer Ouavéné, Abdoulaye Sépou, Jean Chrysostome Gody, Valentin Fikouma, Olivier Hantz, Emmanuel Gordien, Christian Trépo, Fabien Zoulim, Alan Campbell Kay, Paul Dény.

Data curation: Narcisse Patrice Komas, Sumantra Ghosh, Pierre Pradat, Nasser Al Hawajri, Alexandre Manirakiza, Brice Martial Yambyo, Ikram Amri, Tudor Drugan, Alan Campbell Kay, Paul Dény.

Formal analysis: Narcisse Patrice Komas, Sumantra Ghosh, Mariama Abdou-Chekaraou, Pierre Pradat, Nasser Al Hawajri, Gina Laure Laghoe, Jean-Omer Ouavéné, Abdoulaye Sépou, Natali Abeywickrama Samarakoon, Dulce Alfaiate, Caroline Scholtès, Frédéric Le Gal, Christian Trépo, Fabien Zoulim, Paul Dény.
**Funding acquisition:** Narcisse Patrice Komas, Jean-Omer Ouavéné, Abdoulaye Sépou, Jean Chrysostome Gody, Olivier Hantz, Emmanuel Gordien, Philippe Merle, Christian Trépo, Fabien Zoulim, Jean-Claude Cortay, Alan Campbell Kay, Paul Dény.

**Investigation:** Narcisse Patrice Komas, Sumantra Ghosh, Mariama Abdou-Chekaraou, Alexandre Manirakiza, Gina Laure Laghoe, Claudine Bekondi, Ségolène Brichler, Jean-Omer Ouavéné, Abdoulaye Sépou, Brice Martial Yambyio, Jean Chrysostome Gody, Valentin Fikouma, Athénaïs Gerber, Natali Abeywickrama Samarakoon, Dulce Alfaiate, Caroline Scholtès, Nora Martel, Frédéric Le Gal, Hugo Lo Pinto, Ikram Amri, Olivier Hantz, David Durantel, Jean-Louis Lesbordes, Paul Dény.

**Methodology:** Narcisse Patrice Komas, Pierre Pradat, Nasser Al Hawajri, Claudine Bekondi, Brice Martial Yambyio, Caroline Scholtès, Jean-Claude Cortay, Paul Dény.

**Project administration:** Narcisse Patrice Komas, Fabien Zoulim, Paul Dény.

**Resources:** Narcisse Patrice Komas, Claudine Bekondi, Jean-Omer Ouavéné, Jean Chrysostome Gody, Valentin Fikouma, Athénaïs Gerber, Olivier Hantz, David Durantel, Jean-Louis Lesbordes, Tudor Drugan, Christian Trépo, Jean-Claude Cortay, Alan Campbell Kay, Paul Dény.

**Software:** Sumantra Ghosh, Mariama Abdou-Chekaraou, Pierre Pradat, Nasser Al Hawajri, Alexandre Manirakiza, Ségolène Brichler, Brice Martial Yambyio, Athénaïs Gerber, Natali Abeywickrama Samarakoon, Dulce Alfaiate, Caroline Scholtès, Nora Martel, Tudor Drugan, Paul Dény.

**Supervision:** Narcisse Patrice Komas, Sumantra Ghosh, Mariama Abdou-Chekaraou, Pierre Pradat, Claudine Bekondi, Ségolène Brichler, Abdoulaye Sépou, Natali Abeywickrama Samarakoon, Frédéric Le Gal, David Durantel, Emmanuel Gordien, Philippe Merle, Christian Trépo, Jean-Claude Cortay, Paul Dény.

**Validation:** Narcisse Patrice Komas, Sumantra Ghosh, Mariama Abdou-Chekaraou, Pierre Pradat, Nasser Al Hawajri, Alexandre Manirakiza, Gina Laure Laghoe, Claudine Bekondi, Ségolène Brichler, Valentin Fikouma, Athénaïs Gerber, Natali Abeywickrama Samarakoon, Dulce Alfaiate, Caroline Scholtès, Nora Martel, Frédéric Le Gal, Hugo Lo Pinto, Ikram Amri, Olivier Hantz, Philippe Merle, Tudor Drugan, Alan Campbell Kay, Paul Dény.

**Visualization:** Narcisse Patrice Komas, Jean-Omer Ouavéné, Jean-Louis Lesbordes, Paul Dény.

**Writing – original draft:** Narcisse Patrice Komas, Sumantra Ghosh, Mariama Abdou-Chekaraou, Pierre Pradat, Alexandre Manirakiza, Jean Chrysostome Gody, Valentin Fikouma, Dulce Alfaiate, Christian Trépo, Fabien Zoulim, Jean-Claude Cortay, Alan Campbell Kay, Paul Dény.

**Writing – review & editing:** Narcisse Patrice Komas, Fabien Zoulim, Alan Campbell Kay, Paul Dény.

**References**

1. WHO. Global hepatitis report, 2017. Geneva: WHO Press, World Health Organization; 2017.

2. Alfaiate D, Dény P, Durantel D. Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options. Antiviral research. 2015; 122:112–29. https://doi.org/10.1016/j.antiviral.2015.08.009 PMID: 26275800

3. Rizzetto M. The adventure of delta. Liver international: official journal of the International Association for the Study of the Liver. 2016; 36 Suppl 1:135–40.
4. Smedile A, Farci P, Verme G, Caredda F, Cargnel A, Caporaso N, et al. Influence of delta infection on severity of hepatitis B. Lancet (London, England). 1982; 2(8305):945–7.

5. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009; 136(5):1629–38. https://doi.org/10.1053/j.gastro.2009.01.052 PMID: 19208358

6. Abeywickrama-Samarakoon N, Déény P. Epidemiology and Mechanism of Carcigenesis of the virus HBV. In: Droz J, Carme B, Couppié P, Nacher M, Thiébument C, editors. Tropical hematology and Oncology. Switzerland: Springer; 2015. p. 103–16.

7. Stockdale AJ, Chaponda M, Beloukas A, Phillips RO, Matthews PC, Papadimitropoulos A, et al. Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis. The Lancet Global health. 2017; 5(10):e992–e1003. https://doi.org/10.1016/S2214-109X(17)30298-X PMID: 28911765

8. Casey JL, Brown TL, Colan EJ, Wignall FS, Gerin JL. A genotype of hepatitis D virus that occurs in northern South America. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90(19):9016–20. PMID: 8415646

9. Radjen J, Gordien E, Iviuatiushina V, Gault E, Ainais P, Drugan T, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. Journal of virology. 2004; 78(5):2537–44. https://doi.org/10.1128/JVI.78.5.2537-2544.2004 PMID: 14963156

10. Le Gal F, Gault E, Ripault MP, Serpaggi J, Trinchet JC, Gordien E, et al. Eighth major clade for hepatitis delta virus. Emerging infectious diseases. 2006; 12(9):1447–50. https://doi.org/10.3201/eid1209.060112 PMID: 17073101

11. Barros LM, Gomes-Gouvea MS, Pinho JR, Alvarado-Mora MV, Dos Santos A, Mendes-Correia MC, et al. Hepatitis Delta virus genotype 8 infection in Northeast Brazil: inheritance from African slaves? Virus research. 2011; 160(1–2):333–9. https://doi.org/10.1016/j.virusres.2011.07.006 PMID: 21792827

12. Wedemeyer H, Yurdaydin C, Dakekos GN, Erhardt A, Cakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. The New England journal of medicine. 2011; 364(3):32–31. https://doi.org/10.1056/NEJMoa0912696 PMID: 21268724

13. Benes K, Vourli G, Dalekos G, Vasiliadis T, Manolaki N, Hounta A, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. Journal of hepatology. 2013; 59(5):949–56. https://doi.org/10.1016/j.jhep.2013.07.005 PMID: 23850875

14. Abeywickrama-Samarakoon N, Cortay JC, Deny P. The hepatitis D satellite virus of hepatitis B virus: half-opening a new era to control viral infection? Current opinion in infectious diseases. 2016; 29(6):645–53. https://doi.org/10.1097/QCO.0000000000000321 PMID: 27753688

15. Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Shen SW, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006; 130(6):1625–35. https://doi.org/10.1053/j.gastro.2006.01.035 PMID: 16697726

16. Watanabe H, Nagayama K, Enomoto N, Chirnlee R, Yamashiro T, Izumi N, et al. Chronic hepatitis delta virus infection with genotype IIb variant is correlated with progressive liver disease. The Journal of general virology. 2003; 84(Pt 12):3275–3289. https://doi.org/10.1099/jgv.0.19499-0 PMID: 14645909

17. Lesbordes JL, Ravisse P, Georges AJ, Chevailler P, Picoud C, Vitvitski L, et al. Studies on the role of HDV in an outbreak of fulminant hepatitis in Bangui (Central African Republic). Progress in clinical and biological research. 1987; 253:451–8. PMID: 3628412

18. Komass NP, Bai-Sepou S, Manirakiza A, Leale J, Bere A, Le Faou A. The prevalence of hepatitis B virus markers in a cohort of students in Bangui, Central African Republic. BMC infectious diseases. 2010; 10:226. https://doi.org/10.1186/1471-2334-10-226 PMID: 20670399

19. Abdou Chekaraou M, Bricahir S, Mansour W, Le Gal F, Garba A, Deny P, et al. A novel hepatitis B virus (HBV) subgenotype D (D8) strain, resulting from recombination between genotypes D and E, is circulating in Niger along with HBV/E strains. The Journal of general virology. 2010; 91(Pt 6):1609–20. https://doi.org/10.1099/vir.0.018127-0 PMID: 20147517

20. Le Gal F, Badur S, Hawajri NA, Akyuz F, Kaymakoglu S, Bricahir S, et al. Current hepatitis delta virus type 1 (HDV1) infections in central and eastern Turkey indicate a wide genetic diversity that is probably linked to different HDV1 origins. Archives of virology. 2012; 157(4):647–59. https://doi.org/10.1007/s00705-011-1212-8 PMID: 22241621

21. Le Gal F, Gordien E, Affolabi D, Hanksil T, Allou C, Deny P, et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. Journal of clinical microbiology. 2005; 43(5):2363–9. https://doi.org/10.1128/JCM.43.5.2363-2369.2005 PMID: 15872267
22. Andernach IE, Leiss LV, Tarnagda ZS, Tahita MC, Otegbayo JA, Forbi JC, et al. Characterization of hepatitis delta virus in sub-Saharan Africa. Journal of clinical microbiology. 2014; 52(5):1629–36. https://doi.org/10.1128/JCM.02297-13 PMID: 24599979

23. Le Gal F, Brichler S, Druegan T, Alloui C, Roulot D, Pawlotsky JM, et al. Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains. Hepatology (Baltimore, Md). 2017; 66(6):1826–41.

24. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 1995; 20(4):992–1000.

25. Makiala-Mandanda S, Le Gal F, Ngwaka-Matsung N, Ahuka-Mundeke S, Onanga R, Bivigou-Mboumba B. High Prevalence and Diversity of Hepatitis Viruses in Suspected Cases of Yellow Fever in the Democratic Republic of Congo. 2017; 55(5):1299–312. https://doi.org/10.1128/JCM.01847-16 PMID: 28202798

26. Parana R, Gerard F, Lesbordes JL, Pichoud C, Vltivtski L, Lyra LG, et al. Serial transmission of spongio-cytic hepatitis to woodchucks (possible association with a specific delta strain). Journal of hepatology. 1995; 22(4):468–73. PMID: 7665865

27. Buitrago B, Hadler SC, Popper H, Thung SN, Gerber MA, Purcell RH, et al. Epidemiologic aspects of Santa Marta hepatitis over a 40-year period. Hepatology (Baltimore, Md). 1986; 6(6):1292–6.

28. Parana R, Andrade Z, de Freitas LA, Prata A, Kay A, Santos JB. Virological and histological re-evaluation of Labrea hepatitis. Acta gastroenterologica Latinoamericana. 2008; 38(4):284–90. PMID: 19157384

29. Gomes-Gouvea MS, Soares MC, Bensabath G, de Carvalho-Mello IM, Brito EM, Souza OS, et al. Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region. The Journal of general virology. 2009; 90(11):2638–43. https://doi.org/10.1099/vir.0.013615-0 PMID: 19605587

30. Kay A, Melo da Silva E, Pedreira H, Negreiros S, Lobato C, Braga W, et al. HBV/HDV co-infection in the Western Brazilian Amazonia: an intriguing mutation among HDV genotype 3 carriers. Journal of viral hepatitis. 2014; 21(12):921–4. https://doi.org/10.1111/jvh.12267 PMID: 25040045

31. Wu JC, Chen TZ, Huang YS, Yen FS, Ting LT, Sheng WY, et al. Natural history of hepatitis D virus superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology. 1995; 108(3):796–802. PMID: 7875481

32. Andrade ZA, Lesbordes JL, Ravisse P, Parana R, Prata A, Barberino JS, et al. Fulminant hepatitis with microvesicular steatosis (a histologic comparison of cases occurring in Brazil—Labrea hepatitis—and in central Africa—Bangui hepatitis). Revista da Sociedade Brasileira de Medicina Tropical. 1992; 25(3):155–60. PMID: 1308946

33. Wang HC, Wu HC, Chen CF, Fausto N, Lei HY, Su IJ. Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. The American journal of pathology. 2003; 163(6):2441–9. https://doi.org/10.1016/S0002-9440(10)63599-7 PMID: 14633616

34. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. The Lancet Infectious diseases. 2016; 16(12):1399–408. https://doi.org/10.1016/S1473-3099(16)30204-3 PMID: 27633356

35. Komas NP, Vickos U, Hübßchen JM, Béré A, Manirakiza A, Muller CP, Le Faou A. Cross-sectional study of hepatitis B virus infection in rural communities, Central African Republic. BMC Infect Dis. 2013; 13:286. https://doi.org/10.1186/1471-2334-13-286 PMID: 23800310